10th Jul 2020 12:05
IQ-AI Ltd - medical software company- Say it has - in collaboration with its subsidiary Imaging Biometrics LLC - commenced the development of a cancer imaging technology called IB CAD that will detect cancer cells before they are visible on standard imaging. Says technology has the potential to disrupt the way surgery is performed, how radiation treatments are planned, and how treatment therapy is assessed.
"This is a major new development. IB CAD will signify a paradigm shift in brain tumour management and has the potential to enhance IB's leadership position in brain tumour imaging," said Chief Executive Trevor Brown.
Current stock price: 3.64 pence
Year-to-date change: down 14%
By Ife Taiwo; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
IQ-AI